The TechImmune approach targets conserved viral genes as components of a superior next-generation SARS-CoV-2 vaccine, with strong potential to provide broader and more durable protection against variants of concern compared to the standard of care spike-only vaccines.
EST. 2021
TechImmune is advancing the development of a next-generation, broad-spectrum COVID vaccine, designed to obviate the necessity for frequent updating and recurrent boosting that characterize existing vaccines. Our innovative strategy targets multiple antigens to elicit a comprehensive immune response, involving both antibody and T cell activation, in contrast to conventional vaccines that utilize the Spike protein to induce neutralizing antibodies. TechImmune's Coronavirus vaccine encompasses a more advanced approach to enhance long-lasting immunity and disrupt the current booster paradigm.
Mission
To develop and commercialize a next-generation broad-spectrum Covid vaccine to protect the public and economic health of individuals and societies globally. ``INVEST IN A BETTER TOMORROW``
Contact Us
Vision
Despite the rapid introduction of safe and effective vaccines and therapeutics to combat COVID-19, the pandemic continues to circulate worldwide. These vaccines and therapeutics have slowed the progression of the pandemic and blunted the severity of disease, but it has become very clear that the current standard of care is not a long-term solution to the problem, underscoring the desperate need for better medical interventions. TechImmune is developing a next-generation, broad-spectrum covid vaccine that confers potent and broad immunity to provide a long-term solution to current and future outbreaks of CoV. This vaccine could be implemented as a booster of choice and to prevent potential future pandemics.
OUR LEADERSHIP TEAM
Gavin Herbert
EXECUTIVE CHAIRMAN
Mr. Herbert has spent over 50 years in the pharmaceutical industry. He is the co-founder of Allergan Inc., CEO and Chairman of the Board for 30 years. Mr. Herbert served as Executive Vice President of SmithKline Beckman. He received his B.S. in Business, from the University of Southern California.
Jeffrey Ulmer, PhD
CEO and Board Member
Dr. Ulmer has >30 years of experience in Vaccines R&D and most recently served as the Global Head of External Research at Novartis and the Head of Preclinical R&D US at GSK Vaccines. Specialties: Biochemistry, Immunology and Cell Biology. Dr. Ulmer received his PhD from McGill University and post-doctoral fellowship at Yale University School of Medicine.
Richard Haugen
CFO and Board Member
Mr. Haugen was the CEO and President of a public firm, Amylin Pharmaceuticals. He spent 17 years with Allergan Inc. of Irvine culminating that career as Chief Operating Officer of the billion plus global company. He received his B.S. and MBA from the University of Southern California.
Lbachir BenMohamed, PhD
Vice President and Board Member
In 2002, Dr. BenMohamed founded the Cellular & Molecular Immunology Laboratory at UC Irvine. He is the lead investigator for Techlmmune. He is a recipient of several United States National Institute of Health (NIH) grants. He completed his PhD in Immunology at the Pasteur Institute, Paris, France.
Dan Gil, PhD
COO and Board Member
Dr. Gil has had a 30+year career in Pharmaceutical R&D as VP of Research at Allergan. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from University of Pennsylvania.
Dr. Trevor Jones CBE, PhD, DsC
Board Member
Former Head of Research for Burroughs Welcome, UK for over 20 years. Served as Head of British Pharmaceutical Association. He has been an advisor to the UK Government and G7 pandemic preparedness “100” days initiatives
to develop diagnostics, vaccines, and therapeutics for global use.
James Cavanaugh, PhD
Board Member
Dr. Cavanaugh is a Managing Director and Senior Advisor to HealthCare Venture LLC, a private equity and venture capital firm specializing in early stage biotechnology investments. He was previously President of SmithKline & French. He also served as President of Allergan International. Dr. Cavanaugh received his B.S. from Farleigh Dickinson University, M.A. and his Ph.D. from University of Iowa.
Feb 2023
Current Situation and Future Needs
The Need
The Opportunity
GRANTS and CONTRACTS
In February 2023, TechImmune, LLC was awarded a business (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIH) to develop a Universal Vaccine Against Multiple Coronavirus Variants of Concern.
Additional grants are pending.
TechImmune has an exclusive license agreement that covers 6 patent applications. Future government grants are pending in the current year.
FUNDING STRATEGY
TechImmune continues to raise additional funding in the 1st half of 2024.